We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

9 hedge funds and large institutions have $3.9M invested in AYTU BioPharma in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

365% more capital invested

Capital invested by funds: $839K → $3.9M (+$3.06M)

0.03% more ownership

Funds ownership: 0.06% → 0.09% (+0.03%)

10% less funds holding

Funds holding: 10 → 9 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.37M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$35.6K
3
VF
Virtu Financial
New York
+$22.2K
4
SC
Searle & Co
Connecticut
+$18.7K
5
Northern Trust
Northern Trust
Illinois
+$13.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$408K
2
Renaissance Technologies
Renaissance Technologies
New York
-$75K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$35K
4
Citadel Advisors
Citadel Advisors
Florida
-$22K
5
ARTA
A.R.T. Advisors
New York
-$19K

AYTU Hedge Fund Activity: Q1 2019 in Review

9 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2019, worth a combined $3.9M — up 365% from $839K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of AYTU and 4 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was Armistice Capital, adding an estimated $2.37M. The largest seller was Sabby Management, exiting entirely with an estimated $408K sold.

  • 9 institutional investors held AYTU BioPharma (AYTU) as of Q1 2019, down from 10 in Q4 2018.
  • Funds reported $3.9M of AYTU BioPharma stock for Q1 2019, up 365% quarter-over-quarter.
  • 4 funds opened new AYTU BioPharma positions in Q1 2019 and 5 closed out, a net change of -1 holder.
  • The largest AYTU BioPharma buyer in Q1 2019 was Armistice Capital, an estimated $2.37M added.
  • The largest AYTU BioPharma seller in Q1 2019 was Sabby Management, an estimated $408K sold.

Based on aggregated 13F filings for Q1 2019.